VIR-5818
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for VIR-5818, covering 2025-09-24 to 2025-09-24. Get the full timeline:
Most recent: Clinical Trial Update: To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers [Phase 1, Phase 2]